Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP4 | P49662 | 1/20 | 0.53 |
| ▸ | CASP5 | P51878 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.50 |
| ▸ | NCF1 | P14598 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.42 |
| ▸ | HTR3B | O95264 | 3/20 | 0.42 |
| ▸ | HTR3A | P46098 | 3/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250749 | 0.82 | CRHBP (0.59) | CASP1CASP4CASP5HRH4ALDH1A1 | |
| SCHEMBL23299936 | 0.82 | HRH4 (0.57) | CASP1CASP4CASP5HRH4ADRB1 | |
| SCHEMBL30376883 | 0.81 | CASP1 (0.53) | CASP1CASP4CASP5HRH4ADRB1 | |
| SCHEMBL14538233 | 0.81 | CASP1 (0.53) | CASP1CASP4CASP5HRH4ADRB1 | |
| Hydrochloric Acid SCHEMBL15286713 | 0.81 | CASP1 (0.49) | CASP1CASP4CASP5HRH4ADRB1 | |
| SCHEMBL20043262 | 0.79 | CASP1 (0.50) | CASP1CASP4CASP5HRH4ADRB1 | |
| SCHEMBL1617816 | 0.79 | HRH4 (0.72) | CASP1CASP4CASP5HRH4ADRB1 | |
| SCHEMBL3326219 | 0.78 | ADRB1 (0.57) | CASP1CASP4CASP5HRH4ADRB1 | |
| SCHEMBL970205 | 0.78 | KMT2A (0.67) | CASP1HRH4ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL30306132 | 0.77 | GBA1 (0.52) | CASP1CASP4CASP5HRH4ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265086-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| US-8993574-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2283006-B1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2626361-B1 | Pyrrole antifungal agents | F2G LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2097413-B1 | 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-8604029-B2 | 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD BRITISH BODY CORPORATE (GB) | 2013-12-10 | — | — | US | disclosed |
| CN-101679410-B | 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD | 2013-11-27 | — | — | CN | disclosed |
| US-8524705-B2 | 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamide derivatives and related compounds as antifungal agents | F2G LIMITED BRITISH BODY CORPORATE (GB) | 2013-09-03 | — | — | US | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| CN-1839134-A | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2006-09-27 | — | — | CN | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| US-5578596-A | TREATMENT OF SEROTONERGIC NEURON RELATED DISEASES, MOTION SICKNESS, ANXIXETY, DEPRESSION | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0668276-A1 | 2-ALKOXY-5,6,7,8-TETRAHYDROQUINOXALINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | CASP1 2759/4885CASP4 3744/4885CASP5 3862/4885 |
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | CASP1 1314/4885CASP4 2888/4885CASP5 2680/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | CASP1 2759/4885CASP4 3744/4885CASP5 3862/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | CASP1 2759/4885CASP4 3744/4885CASP5 3862/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | CASP1 311/4885CASP4 2599/4885CASP5 1350/4885 |
| US-20230265086-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | ATG7, ULK1, BECN1 | CASP1 1615/4885CASP4 1413/4885CASP5 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.